NASDAQ:ABCL AbCellera Biologics (ABCL) Stock Price, News & Analysis $11.82 +0.45 (+3.96%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$11.78 -0.04 (-0.34%) As of 10/23/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AbCellera Biologics Stock (NASDAQ:ABCL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AbCellera Biologics alerts:Sign Up Key Stats Today's Range$11.08▼$11.9050-Day Range$10.46▼$14.8252-Week Range$2.74▼$15.02Volume3.02 million shsAverage Volume5.28 million shsMarket Capitalization$3.62 billionP/E RatioN/ADividend YieldN/APrice Target$13.89Consensus RatingModerate Buy Company Overview AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, British Columbia, that develops antibody-based medicines and provides antibody discovery services to pharmaceutical and biotechnology companies. Its platform is designed to identify therapeutic antibodies from immune cells and accelerate their progression from discovery through development. The company combines high-throughput screening, microfluidics, single-cell analysis, automation, and artificial intelligence to evaluate large numbers of antibody candidates. Its services include antibody discovery, screening, characterization, optimization, and assessment of properties such as specificity, potency, and developability. AbCellera also uses its technology to advance an internal pipeline of antibody therapeutics. Founded in 2012 by Carl Hansen, AbCellera has collaborated with biopharmaceutical companies worldwide. The company’s technology contributed to the discovery of bamlanivimab, an antibody developed with Eli Lilly for the treatment of COVID-19. AbCellera became a publicly traded company on the Nasdaq under the symbol ABCL in 2020.AI Generated. May Contain Errors. Read More AbCellera Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreABCL MarketRank™: 2.821828358205 of 5 starsAbCellera Biologics scored higher than 56% of companies evaluated by MarketBeat, and ranked 413th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingAbCellera Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 2 strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAbCellera Biologics has a consensus price target of $13.89, representing about 17.5% upside from its current price of $11.82.Amount of Analyst CoverageAbCellera Biologics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AbCellera Biologics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for AbCellera Biologics are expected to decrease in the coming year, from ($0.69) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AbCellera Biologics is -21.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AbCellera Biologics is -21.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbCellera Biologics has a P/B Ratio of 3.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AbCellera Biologics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.80% of the float of AbCellera Biologics has been sold short.Short Interest Ratio / Days to CoverAbCellera Biologics has a short interest ratio ("days to cover") of 5.98.Change versus previous monthShort interest in AbCellera Biologics has recently decreased by 4.22%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbCellera Biologics does not currently pay a dividend.Dividend GrowthAbCellera Biologics does not have a long track record of dividend growth. News and Social Media4.1 / 5News SentimentN/A News SentimentAbCellera Biologics has a news sentiment score of 1.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for AbCellera Biologics this week, compared to 4 articles on an average week.Search Interest13 people have searched for ABCL on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.MarketBeat Follows6 people have added AbCellera Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AbCellera Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders28.40% of the stock of AbCellera Biologics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.42% of the stock of AbCellera Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AbCellera Biologics' insider trading history. Receive ABCL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AbCellera Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABCL Stock News HeadlinesAbCellera Has Promising Menopause Data, But Much Of The Opportunity Is Priced InOctober 22 at 4:45 AM | seekingalpha.comAbCellera Biologics' ABCL635 Seen With Best-in-Class Potential in Menopause, UBS SaysOctober 13, 2026 | finance.yahoo.comLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time.October 24 at 1:00 AM | Profits Run (Ad)UBS Initiates AbCellera Biologics at Buy With $18 Price TargetOctober 12, 2026 | marketscreener.comMAbCellera Biologics (ABCL) Could Be 27% Undervalued As ABCL635 Data Draws FocusOctober 9, 2026 | finance.yahoo.comAbCellera to Present Phase 1/2 ABCL635 Data at Menopause Society MeetingOctober 9, 2026 | marketscreener.comMAbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual MeetingOctober 8, 2026 | businesswire.comAbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026October 1, 2026 | businesswire.comSee More Headlines ABCL Stock Analysis - Frequently Asked Questions How have ABCL shares performed this year? AbCellera Biologics' stock was trading at $3.42 on January 1st, 2026. Since then, ABCL stock has increased by 245.6% and is now trading at $11.82. How were AbCellera Biologics' earnings last quarter? AbCellera Biologics Inc. (NASDAQ:ABCL) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.02. The company earned $4.05 million during the quarter, compared to the consensus estimate of $7.85 million. AbCellera Biologics had a negative trailing twelve-month return on equity of 17.49% and a negative net margin of 248.83%. Read the conference call transcript. When did AbCellera Biologics IPO? AbCellera Biologics (ABCL) raised $423 million in an initial public offering (IPO) on Friday, December 11th 2020. The company issued 24,150,000 shares at $17.00-$18.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets served as the underwriters for the IPO. Who are AbCellera Biologics' major shareholders? AbCellera Biologics' top institutional shareholders include TD Waterhouse Canada Inc. (3.01%), Citizens Financial Group Inc. RI (0.06%), Green Alpha Advisors LLC (0.01%) and SBI Securities Co. Ltd.. View institutional ownership trends. How do I buy shares of AbCellera Biologics? Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AbCellera Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that AbCellera Biologics investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), NIO (NIO) and Taiwan Semiconductor Manufacturing (TSM). Company Calendar Last Earnings8/05/2026Today10/24/2026Next Earnings (Confirmed)11/09/20262026 Stifel Healthcare Conference11/11/2026Jefferies Global Healthcare Conference11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ABCL's financial health is in the Green zone, according to TradeSmith. ABCL has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ABCL CIK1703057 Webwww.abcellera.com Phone604-559-9005FaxN/AEmployees562Year Founded2012Price Target and Rating Average Price Target for AbCellera Biologics$13.89 High Price Target$30.00 Low Price Target$4.00 Potential Upside/Downside+17.5%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$146.41 million Net Margins-248.83% Pretax Margin-297.36% Return on Equity-17.49% Return on Assets-12.36% Debt Debt-to-Equity RatioN/A Current Ratio12.77 Quick Ratio12.77 Sales & Book Value Annual Sales$66.17 million Price / Sales54.77 Cash FlowN/A Price / Cash FlowN/A Book Value$3.23 per share Price / Book3.66Miscellaneous Outstanding Shares306,611,000Free Float219,533,000Market Cap$3.62 billion OptionableOptionable Beta1.41 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:ABCL) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | Sponsored$29.97 or $0 todayThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
